-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In high-income countries, at least one-third of adults who have strokes caused by spontaneous (non-traumatic) intracerebral hemorrhage (ICH) have been taking oral antithrombotic therapy due to their comorbidities and other risk factors for vascular diseases ( Antiplatelet or anticoagulant) medications .
Vascular Thrombosis Myocardial Infarction
Antiplatelet drugs may benefit survivors of spontaneous ICH, but their impact on major vascular events is uncertain
RESTART included ICH survivors on antithrombotic therapy to estimate the impact of initiating and avoiding antiplatelet therapy on recurrent symptomatic ICH, and whether this risk may exceed any reduction in occlusive vascular events
After a median follow-up of 537 participants for 2 years, the main results of RESTART ruled out all risks, but there was a very small increase in the risk of recurrence of ICH after antiplatelet therapy (adjusted hazard ratio [HR] , 0.
prevention
Participants were followed for up to 7 years for primary outcomes (recurrent symptomatic ICH) and secondary outcomes (all major vascular events)
A total of 537 patients (median age, 76.
The main result of recurrent ICH affected 22 of the 268 participants (8.
Major vascular events affected 72 participants (26.
Major vascular events affected 72 participants (26.
This study found that antiplatelet therapy had no statistically significant effect on recurrent ICH or all major vascular events
Original Source:
Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage: Extended Follow-up of the RESTART Randomized Clinical Trial.
JAMA
is here to leave a message